(Q36382235)

13 August 2017

1 reference

title

Therapy of hepatitis C: from empiricism to eradication (English)

1 reference

13 August 2017

0 references

Jean-Michel Pawlotsky

series ordinal

1

object named as

Jean-Michel Pawlotsky

0 references

author name string

Jean-Michel Pawlotsky

series ordinal

1

1 reference

PubMed ID

16447262

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

43

1 reference

13 August 2017

S207-20

1 reference

13 August 2017

2 Suppl 1

1 reference

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

13 August 2017

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway

21 January 2018

1 reference

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

21 January 2018

1 reference

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

7 January 2021

Therapy of hepatitis C: overview

1 reference

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

7 January 2021

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

1 reference

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

7 January 2021

Current and future concepts in hepatitis C therapy

1 reference

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

7 January 2021

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

1 reference

7 January 2021

Complete replication of hepatitis C virus in cell culture

1 reference

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

7 January 2021

Actions of cytokines on the immune response and viral interactions: an overview

1 reference

7 January 2021

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

7 January 2021

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

7 January 2021

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

7 January 2021

Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis

1 reference

7 January 2021

FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis?

1 reference

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

1 reference

7 January 2021

Use of virologic assays in the diagnosis and management of hepatitis C virus infection

1 reference

7 January 2021

New kinetic models for the hepatitis C virus

1 reference

7 January 2021

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.

1 reference

7 January 2021

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

1 reference

7 January 2021

Pure red-cell aplasia and epoetin therapy.

1 reference

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

1 reference

7 January 2021

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

1 reference

7 January 2021

Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

7 January 2021

Treatment of patients with hepatitis C virus on the waiting list

1 reference

7 January 2021

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

1 reference

7 January 2021

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

1 reference

7 January 2021

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial

1 reference

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

7 January 2021

Treatment of hepatitis C in patients who have decompensated cirrhosis

1 reference

7 January 2021

Hepatitis C virus kinetics during and immediately after liver transplantation.

1 reference

7 January 2021

Treatment of recurrent hepatitis C after liver transplantation

1 reference

7 January 2021

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

1 reference

7 January 2021

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation

1 reference

7 January 2021

Outcomes of acute rejection after interferon therapy in liver transplant recipients.

1 reference

7 January 2021

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

1 reference

7 January 2021

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.

1 reference

7 January 2021

Treatment of hepatitis C in potential kidney and heart transplant patients

1 reference

7 January 2021

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

1 reference

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

7 January 2021

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

1 reference

7 January 2021

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

1 reference

7 January 2021

The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis

1 reference

7 January 2021

Structural biology of hepatitis C virus

1 reference

7 January 2021

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

7 January 2021

Robust hepatitis C virus infection in vitro

1 reference

7 January 2021

Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy

1 reference

7 January 2021

Hepatitis C virus genetic variability: pathogenic and clinical implications

1 reference

7 January 2021

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

1 reference

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

7 January 2021

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

7 January 2021

Development of a hepatitis C virus vaccine

1 reference

7 January 2021

Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.

1 reference

7 January 2021

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21064

1 reference

13 August 2017

1 reference

PubMed ID

16447262